Ginkgo Results Presentation Deck
Adjusted EBITDA Reconciliation (Unaudited)
Three Months Ended
December 31,
2021
In millions of USD
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders
Interest income
Interest expense
Income tax (benefit) provision
Depreciation and amortization
EBITDA
Stock-based compensation (¹)
Loss on equity method investments (2)
Loss (gain) on investments (3)
Change in fair value of warrant liabilities
Gain on settlement of partnership agreement
Other (4)
Adjusted EBITDA
$ (1,600.7)
(0.5)
0.6
(0.7)
8.0
$ (1,593.3)
1,672.8
4.1
14.6
(77.1)
(22.8)
2.3
$ 0.6
2020
$ (46.9)
(0.1)
0.6
0.0
4.0
$ (42.5)
0.1
(1.2)
(1.2)
0.0
(0.7)
(5.3)
$ (50.8)
Year Ended
December 31,
2021
$ (1,830.0)
(0.8)
2.4
(1.5)
29.1
$ (1,800.9)
1,687.6
74.4
11.5
(58.6)
(23.8)
3.7
$ (106.0)
2020
$ (126.6)
(2.6)
2.4
1.9
13.9
$ (111.1)
0.5
0.3
3.7
0.0
(8.3)
(6.6)
$ (121.4)
(1) For the three months ended and the year ended December 31, 2021, includes $5 0 million in employer payroll taxes related to stock-based compensation
(2)
For the three months ended December 31, 2021 and 2020, represents losses on equity method investments under the hypothetical liquidation at book value ("HLBV") method of $4 7 million and $1 8 million, respectively, net of losses attributable to
non-controlling interests For the years ended December 31, 2021 and 2020, represents losses on equity method investments under the HLBV method of $77 3 million and $0 4 million, respectively, net of losses attributable to non-controlling interests
(3) Includes loss on the change in fair value of our common stock investments in Synlogic and Cronos and warrants to purchase Synlogic common stock, which are all carried at fair value
(4)
For the three months ended and the year ended December 31, 2021, includes mark-to-market adjustments on Access Bio convertible notes and the Glycosyn promissory note For the three months ended and the year ended December 31, 2020, primarily
includes milestone payments under our agreement with the National Institutes of Health
38
Property of Ginkgo Bioworks
2021 UPDATE & BUSINESS REVIEWView entire presentation